Scaling Artificial Intelligence for Prostate Cancer Detection on MRI towards Organized Screening and Primary Diagnosis in a Global, Multiethnic Population (Study Protocol)
In this intercontinental, confirmatory study, we include a retrospective cohort of 22,481 MRI examinations (21,288 patients; 46 cities in 22 countries) to train and externally validate the PI-CAI-2B model, i.e., an efficient, next-generation iteration of the state-of-the-art AI system that was developed for detecting Gleason grade group $\geq$2 prostate cancer on MRI during the PI-CAI study. Of these examinations, 20,471 cases (19,278 patients; 26 cities in 14 countries) from two EU Horizon projects (ProCAncer-I, COMFORT) and 12 independent centers based in Europe, North America, Asia and Africa, are used for training and internal testing. Additionally, 2010 cases (2010 patients; 20 external cities in 12 countries) from population-based screening (STHLM3-MRI, IP1-PROSTAGRAM trials) and primary diagnostic settings (PRIME trial) based in Europe, North and South Americas, Asia and Australia, are used for external testing. Primary endpoint is the proportion of AI-based assessments in agreement with the standard of care diagnoses (i.e., clinical assessments made by expert uropathologists on histopathology, if available, or at least two expert urogenital radiologists in consensus; with access to patient history and peer consultation) in the detection of Gleason grade group $\geq$2 prostate cancer within the external testing cohorts. Our statistical analysis plan is prespecified with a hypothesis of diagnostic interchangeability to the standard of care at the PI-RADS $\geq$3 (primary diagnosis) or $\geq$4 (screening) cut-off, considering an absolute margin of 0.05 and reader estimates derived from the PI-CAI observer study (62 radiologists reading 400 cases). Secondary measures comprise the area under the receiver operating characteristic curve (AUROC) of the AI system stratified by imaging quality, patient age and patient ethnicity to identify underlying biases (if any).
Code (0)
등록된 구현이 없습니다.
Similar Papers 제목 키워드 기반
Critical Evaluation of Artificial Intelligence as Digital Twin of Pathologist for Prostate Cancer Pathology
Prostate cancer pathology plays a crucial role in clinical management but is time-consuming. Artificial intelligence (AI) shows promise in detecting prostate cancer and grading patterns. We tested an AI-based digital twi…
Overcoming Limitations in Artificial Intelligence-based Prostate Cancer Detection through Better Datasets and a Bayesian Approach to Aggregate Panel Predictions
Despite considerable progress in developing artificial intelligence (AI) algorithms for prostate cancer detection from whole slide images, the clinical applicability of these models remains limited due to variability in …
Diagnosticwhole slide imagesAI-based Automatic Segmentation of Prostate on Multi-modality Images: A Review
Prostate cancer represents a major threat to health. Early detection is vital in reducing the mortality rate among prostate cancer patients. One approach involves using multi-modality (CT, MRI, US, etc.) computer-aided d…
Image SegmentationSegmentationSemantic SegmentationSurveyANNCRIPS: Artificial Neural Networks for Cancer Research In Prediction & Survival
Prostate cancer is a prevalent malignancy among men aged 50 and older. Current diagnostic methods primarily rely on blood tests, PSA:Prostate-Specific Antigen levels, and Digital Rectal Examinations (DRE). However, these…
DiagnosticDevelopment and prospective validation of a prostate cancer detection, grading, and workflow optimization system at an academic medical center
Artificial intelligence may assist healthcare systems in meeting increasing demand for pathology services while maintaining diagnostic quality and reducing turnaround time and costs. We aimed to investigate the performan…
DiagnosticSensitivitySpecificity